Lapatinib
Trovati 8 articoli
- Tykerb blocks the growth of breast cancer cells that spread to the brain in a mouse model
- Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain. The small molecule used in the studies was... (Leggi Articolo)
- Lapatinib in brain metastases associated with breast cancer
- One-third of women with HER2-positive metastatic breast cancer currently develop brain metastases. Once the disease advances to this stage, overall disease prognosis is poor with the average one-year survival from diagnosis estimated at about 20 percent. Results from an ongoing, multicenter ... (Leggi Articolo)
- Lapatinib in combination with Paclitaxel as first-line treatment for patients with metastatic or relapsed advanced breast cancer
- Paclitaxel ( Taxol ) is one of the most commonly used chemotherapies in breast cancer. Therefore, the evaluation of Lapatinib ( Tykerb ) in combination with this treatment is of high importance. A large, randomized, multicenter, prospective trial evaluated a total of 580 patients either negat... (Leggi Articolo)
- Advanced breast tumor: FDA has approved Tykerb
- The FDA ( Food and Drug Administration ) has approved Tykerb ( Lapatinib ), a new targeted anti-cancer treatment, to be used in combination with Capectabine ( Xeloda ), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive. The combination treatment is ... (Leggi Articolo)
- Advanced breast cancer: Tykerb an alternative to Herceptin
- A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive ... (Leggi Articolo)
- Advanced breast cancer: Tykerb an alternative to Herceptin
- A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive ... (Leggi Articolo)
- Advanced renal cell carcinoma: efficacy of Lapatinib in patients with high EGFR expression
- A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow despite standard therapy. The patients in the study who responded favorably to this drug had tumor... (Leggi Articolo)
- Liver cancer: skin rash in patients treated with Lapatinib linked to response to treatment
- In a study of a new drug for liver cancer, researchers found that the development of a skin rash correlated directly with the patient's response to treatment. Patients who developed a rash lived twice as long as those who did not. The study included 57 patients with advanced liver, gallbladd... (Leggi Articolo)
